The use of tafasitamab in diffuse large B-cell lymphoma

Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have poor prognoses, especially when they are not candidates for autologous stem cell transplant (ASCT). Tafasitamab is a humanized monoclonal anti-CD19 antibody that has recently bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Düll, Johannes, Topp, Max, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264734/
https://www.ncbi.nlm.nih.gov/pubmed/34285786
http://dx.doi.org/10.1177/20406207211027458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264734/
https://www.ncbi.nlm.nih.gov/pubmed/34285786
http://dx.doi.org/10.1177/20406207211027458

Ejemplares similares